Margetuximab does not improve pCR rate in HER2-positive early breast cancer

As a new type of monoclonal antibody, margetuximab (margetuximab-cmkb) has recently received widespread attention for its efficacy in HER2-positive early-stage breast cancer patients. However, the results of the MARGOT/TBCRC052 trial showed that margetuximab did not significantly improve the pathological complete response (pCR) rate in these patients compared with traditional trastuzumab.

1. Research background

MARGOT/TBCRC052 is a randomized phase 2 clinical trial designed to evaluate the efficacy of margetuximab versus trastuzumab in patients with early-stage HER2-positive breast cancer who carry the CD16A F allele. The previous phase 3 SOPHIA trial showed that margetuximab was more effective than trastuzumab in patients with metastatic HER2-positive breast cancer, providing a theoretical basis for this study.

2. Research design

The clinical trial recruited171 patients with stage II-III HER2-positive breast cancer who did not receive any treatment at the time of enrollment. Participants' CD16A genotypes included FF or FV, a genotype that has been suggested in previous studies to affect antibody-dependent cell-mediated cytotoxicity (ADCC). Approximately 80% of patients, with an average age of 52 to 55 years, had clinical T2 tumors, 63%-69% were stage N0, and 85% were clinical stage II. These data indicate that the study sample is representative and reflects the characteristics of patients with early-stage HER2-positive breast cancer.

Participants were randomly assigned to two groups: one group received neoadjuvant paclitaxel/magituximab/pertuzumab (TMP), and the other group received neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP). This design not only examines the efficacy of different treatment options, but also provides the possibility for subsequent biomarker analysis.

3. Result analysis

The main conclusion of the study is "TMP does not provide a statistically significant improvement in pCR rate compared with THP." Nonetheless, the research team noted a 10% numerical improvement in pCR rate in the TMP group (P=0.25), suggesting that further in-depth analysis may be needed to explore subtle differences between the two groups.

It is worth noting that both treatment regimens were well tolerated, and The incidence of infusion-related reactions in the TMP group was increased, but this phenomenon was controllable. This shows that although the effect of magetuximab is not significantly better than trastuzumab, its safety is guaranteed, providing a possible basis for subsequent application.

4. Further research directions

Based on the results ofMARGOT/TBCRC052 trial, future research can focus on the following aspects:

1. Analysis of biomarkers: Although the current results failed to show significant differences, comparison of circulating and tissue immune biomarkers may reveal deeper mechanisms. Through further analysis of immune-related markers, researchers may be able to find the key factors affecting the pCR rate, thereby providing more basis for personalized treatment.

2. Long-term efficacy tracking: In addition to focusing on the short-termpCR rate, long-term survival rate and recurrence rate data will help evaluate the actual clinical value of margetuximab. Follow-up studies should include long-term follow-up to observe the impact of different treatment options on the overall survival of patients.

3. Studies in different subgroups: Considering the diversity of participants' hormone receptor status andCD16A genotype, future studies can analyze different subgroups to determine which specific groups may benefit from margetuximab.

The results of the MARGOT/TBCRC052 trial provide a new perspective on the treatment of HER2-positive early breast cancer. Although margetuximab did not show a significant advantage in improving pCR rates, its good tolerability and potential numerical improvement suggest the need for further studies. With in-depth analysis of biomarkers and long-term effects, it may lead to new breakthroughs in the treatment of HER2-positive breast cancer.

Reference materials:https://www.physiciansweekly.com/margetuximab-does-not-improve-pcr-rate-in-her2-positive-early-breast-cancer/